335 related articles for article (PubMed ID: 30017331)
1. Single centre guidelines for radiological follow-up based on 775 patients treated by cytoreductive surgery and HIPEC for appendiceal pseudomyxoma peritonei.
Govaerts K; Chandrakumaran K; Carr NJ; Cecil TD; Dayal S; Mohamed F; Thrower A; Moran BJ
Eur J Surg Oncol; 2018 Sep; 44(9):1371-1377. PubMed ID: 30017331
[TBL] [Abstract][Full Text] [Related]
2. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours.
Ansari N; Chandrakumaran K; Dayal S; Mohamed F; Cecil TD; Moran BJ
Eur J Surg Oncol; 2016 Jul; 42(7):1035-41. PubMed ID: 27132072
[TBL] [Abstract][Full Text] [Related]
4. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
Lord AC; Shihab O; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
Eur J Surg Oncol; 2015 Mar; 41(3):396-9. PubMed ID: 25216980
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin.
Delhorme JB; Severac F; Averous G; Glehen O; Passot G; Bakrin N; Marchal F; Pocard M; Lo Dico R; Eveno C; Carrere S; Sgarbura O; Quenet F; Ferron G; Goéré D; Brigand C;
Br J Surg; 2018 May; 105(6):668-676. PubMed ID: 29412465
[TBL] [Abstract][Full Text] [Related]
6. Huge pseudomyxoma peritonei: Surgical strategies and procedures to employ to optimize the rate of complete cytoreductive surgery.
Benhaim L; Honoré C; Goéré D; Delhorme JB; Elias D
Eur J Surg Oncol; 2016 Apr; 42(4):552-7. PubMed ID: 26868165
[TBL] [Abstract][Full Text] [Related]
7. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients.
Taflampas P; Dayal S; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
Eur J Surg Oncol; 2014 May; 40(5):515-520. PubMed ID: 24462284
[TBL] [Abstract][Full Text] [Related]
8. Appendiceal pseudomyxoma peritonei: predictors of recurrence and iterative surgery.
Kong JC; Flood MP; Guerra GR; Liesegang A; Wong WJ; Mitchell C; Warrier SK; Naidu S; Meade B; Lutton N; Heriot AG
Colorectal Dis; 2021 Sep; 23(9):2368-2375. PubMed ID: 34157209
[TBL] [Abstract][Full Text] [Related]
9. [A single-center clinical analysis of 65 cases of pseudomyxoma peritonei from appendiceal origin in the early stage].
Ma RQ; Xia A; Zhai XC; Chen F; Xu HB
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):698-702. PubMed ID: 31550861
[No Abstract] [Full Text] [Related]
10. Development and Validation of Nomograms to Predict Survival in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin.
Chandrakumaran K; Carr NJ; Mohamed F; Cecil TD; Moran BJ
JAMA Surg; 2023 May; 158(5):522-530. PubMed ID: 36920381
[TBL] [Abstract][Full Text] [Related]
11. Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei.
Beane JD; Wilson GC; Sutton JM; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Holtzman MP; Zureikat AJ; Ahrendt SA; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2019 May; 26(5):1429-1436. PubMed ID: 30623341
[TBL] [Abstract][Full Text] [Related]
12. Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study.
Baratti D; Kusamura S; Milione M; Pietrantonio F; Caporale M; Guaglio M; Deraco M
Ann Surg Oncol; 2016 Dec; 23(13):4222-4230. PubMed ID: 27352203
[TBL] [Abstract][Full Text] [Related]
13. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
[TBL] [Abstract][Full Text] [Related]
14. The pre-operative neutrophil-lymphocyte ratio predicts overall and disease-free survival following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with pseudomxyoma peritonei of appendiceal origin.
Rangarajan K; Chandrakumaran K; Dayal S; Mohamed F; Moran BJ; Cecil TD
Int J Hyperthermia; 2018 Aug; 34(5):559-563. PubMed ID: 29063804
[TBL] [Abstract][Full Text] [Related]
15. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M
Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742
[TBL] [Abstract][Full Text] [Related]
16. Surveillance of Low-Grade Appendiceal Mucinous Neoplasms With Peritoneal Metastases After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Are 5 Years Enough? A Multisite Experience.
Solomon D; Bekhor E; Leigh N; Maniar YM; Totin L; Hofstedt M; Aycart SN; Carr J; Ballentine S; Magge DR; Golas BJ; Pai RK; Polydorides AD; Bartlett DL; Labow DM; Choudry HA; Sarpel U
Ann Surg Oncol; 2020 Jan; 27(1):147-153. PubMed ID: 31385130
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of cytoreductive surgery and HIPEC for pseudomyxoma peritonei of appendiceal origin from two Indian centers: A preliminary five-year experience.
Bhatt A; Sheshadri D; Chandan G; Ramaswamy V; Pandey J; Bhorkar N; Agrawal D; Mehta S
J BUON; 2017; 22(1):251-257. PubMed ID: 28365962
[TBL] [Abstract][Full Text] [Related]
18. Managing Recurrent Pseudomyxoma Peritonei in 430 Patients After Complete Cytoreduction and HIPEC: A Dilemma for Patients and Surgeons.
Ahmadi N; Kostadinov D; Sakata S; Ball WR; Gandhi J; Carr NJ; Tzivanakis A; Dayal SP; Mohamed F; Cecil TD; Moran BJ
Ann Surg Oncol; 2021 Nov; 28(12):7809-7820. PubMed ID: 34041626
[TBL] [Abstract][Full Text] [Related]
19. The modified Glasgow prognosis score predicts for overall and disease-free survival following cytoreductive surgery and HIPEC in patients with pseudomyxoma peritonei of appendiceal origin.
Tan GH; Novo CA; Dayal S; Chandrakumaran K; Mohamed F; Cecil T; Moran BJ
Eur J Surg Oncol; 2017 Feb; 43(2):388-394. PubMed ID: 27866811
[TBL] [Abstract][Full Text] [Related]
20. Twenty-years' experience with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP).
Papantoni E; Ntatsis K; Kyziridis D; Kalakonas A; Hristakis C; Tentes AA
J BUON; 2021; 26(4):1647-1652. PubMed ID: 34565031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
